SPRY Stock Forecast: ARS Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.96
−11.90% on the day

The median 12-month analyst price target for ARS Pharmaceuticals, Inc. is $17. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 13 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$297.6M
Ticker Nerd rank
13/ 100
Median analyst target
$17
Analysts covering
4
Revenue$33.7M+114.2% y/y
Operating income−$61.5M
Net income−$62.3M
Free cash flow−$60.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−23.9%
1M
−31.0%
YTD
−74.6%
1Y
−56.0%
From 52W high
−77.3%
From 52W low
+11.7%
$3
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores ARS Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
13/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
44
Value
41
Revisions
38
Quality
31
Volatility
31
Issuance
23
Growth
16
Momentum
10

Accruals (44): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SPRY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPRY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26SPRYHigh $20Median $17Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$14
Low
$17
Median
$20
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
6 Nov 2026Cantor FitzgeraldMaintainsOverweight$30 → $20
6 Nov 2026Raymond JamesDowngradeOutperform$28 → $17
13 Aug 2026Leerink PartnersMaintainsOutperform$24 → $18
25 June 2026Leerink PartnersMaintainsOutperform$25 → $24
28 May 2026Cantor FitzgeraldMaintainsOverweight—
4 Sept 2025Roth CapitalInitiatesBuy—
7 Mar 2025ScotiabankInitiatesSector Outperform—
14 Jan 2025Raymond JamesMaintainsStrong Buy—
13 Jan 2025Leerink PartnersMaintainsOutperform—
8 Oct 2024Cantor FitzgeraldReiteratesOverweight—
20 Sept 2024Leerink PartnersMaintainsOutperform—
16 Sept 2024Cantor FitzgeraldReiteratesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
20 Aug 2024Cantor FitzgeraldInitiatesOverweight—
13 Aug 2024Raymond JamesUpgradeStrong Buy—
25 July 2024Raymond JamesInitiatesOutperform—
11 Mar 2024WedbushReiteratesOutperform—
5 Mar 2024Leerink PartnersUpgradeOutperform—
13 Nov 2023WedbushMaintainsOutperform—
21 Sept 2023WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SPRY.

Market Radar

This page is one stock. Monday covers all of them.

SPRY appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SPRY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, ARS Pharmaceuticals, Inc. returned −56.0% against +6.9% for the S&P 500, dividends included.

SPRY vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26SPRYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SPRY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
2.4×

Cheaper than 43% of US stocks

Price / book
23.4×

Cheaper than 3% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
61.8%

Higher than 75% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−294.6%

Higher than 5% of US stocks

Return on assets
−39.5%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ARS Pharmaceuticals, Inc. has a market value of $297.6M and an enterprise value of $356.2M.

  • Revenue in the twelve months to 30 June 2026: $116.9M. The latest quarter grew 114.2% year on year.

  • Net income over the same four quarters: −$215.4M, a −184.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$196.6M.

  • Shares outstanding: 99.4M.

  • ARS Pharmaceuticals, Inc. employs 203 people — $576K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

SPRY and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPRYARS Pharmaceuticals, Inc.$297.6M13
XFORX4 Pharmaceuticals, Inc.$297.4M65
EVMNEvommune, Inc.$291.1M11
SLBTSL Science Holding Ltd.$308.4M0
BNTCBenitec Biopharma, Inc.$285.9M39
GLSIGreenwich LifeSciences, Inc.$282.6M53
PROKProKidney Corp.$313.9M17

Take a look at SPRY’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own ARS Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SPRY

What is the SPRY stock price forecast for 2026-2027?

The median 12-month analyst price target for ARS Pharmaceuticals, Inc. is $17, with estimates ranging from $14 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPRY stock a buy right now?

Of the 4 analysts covering ARS Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ARS Pharmaceuticals, Inc. 13 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPRY?

As at 21 Nov 2026, ARS Pharmaceuticals, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (44 of 100).

Will SPRY stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $17, and Ticker Nerd's factor model ranks ARS Pharmaceuticals, Inc. 13 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPRY stock forecast for 2030?

No analyst covering ARS Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $20 over the next 12 months.

How has SPRY stock performed over the past year?

ARS Pharmaceuticals, Inc. returned -56.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ARS Pharmaceuticals, Inc. do?

Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention.

Company

About ARS Pharmaceuticals, Inc.

Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention. Notable for its emphasis on creating user-friendly delivery mechanisms, Ars Pharmaceuticals tailors its offerings to both patients and healthcare professionals seeking reliable and effective emergency treatments. By addressing critical needs within the healthcare industry, Ars Pharmaceuticals plays a significant role in expanding options in allergy treatment and management. Its contributions to the medical field underscore its ongoing commitment to transforming therapeutic landscapes and meeting pressing health challenges.

CEO Mr. Donn Casale · 203 employees · United States · https://ars-pharma.com